Abstract
Introduction: The authors discuss a novel patient controlled analgesia system utilizing a preprogrammed device that delivers a small submucosal tablet of sufentanil.Areas covered: This submucosal sufentanil system is not yet commercially available. A literature review of the current patient controlled analgesia systems and current information of this device are discussed.Expert opinion: This novel device has the potential to enhance patient safety as it is preprogrammed and delivers a standard dose of sufentanil, a rapidly acting opioid devoid of active metabolites.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 845-851 |
| Number of pages | 7 |
| Journal | Expert Opinion on Drug Delivery |
| Volume | 12 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2015 |
Fingerprint
Keywords
- Microtablet
- Pain
- Sublingual
- Sufentanil
ASJC Scopus subject areas
- Pharmaceutical Science
Cite this
The role of sublingual sufentanil nanotabs for pain relief. / Minkowitz, Harold S.; Candiotti, Keith A.
In: Expert Opinion on Drug Delivery, Vol. 12, No. 5, 01.05.2015, p. 845-851.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The role of sublingual sufentanil nanotabs for pain relief
AU - Minkowitz, Harold S.
AU - Candiotti, Keith A
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Introduction: The authors discuss a novel patient controlled analgesia system utilizing a preprogrammed device that delivers a small submucosal tablet of sufentanil.Areas covered: This submucosal sufentanil system is not yet commercially available. A literature review of the current patient controlled analgesia systems and current information of this device are discussed.Expert opinion: This novel device has the potential to enhance patient safety as it is preprogrammed and delivers a standard dose of sufentanil, a rapidly acting opioid devoid of active metabolites.
AB - Introduction: The authors discuss a novel patient controlled analgesia system utilizing a preprogrammed device that delivers a small submucosal tablet of sufentanil.Areas covered: This submucosal sufentanil system is not yet commercially available. A literature review of the current patient controlled analgesia systems and current information of this device are discussed.Expert opinion: This novel device has the potential to enhance patient safety as it is preprogrammed and delivers a standard dose of sufentanil, a rapidly acting opioid devoid of active metabolites.
KW - Microtablet
KW - Pain
KW - Sublingual
KW - Sufentanil
UR - http://www.scopus.com/inward/record.url?scp=84928329654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928329654&partnerID=8YFLogxK
U2 - 10.1517/17425247.2015.975202
DO - 10.1517/17425247.2015.975202
M3 - Article
C2 - 25388859
AN - SCOPUS:84928329654
VL - 12
SP - 845
EP - 851
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
SN - 1742-5247
IS - 5
ER -